唾液腺灌洗缓解干燥综合征患者口干:随访40周的单盲随机对照临床试验

doi:10.13591/j.cnki.kqyx.2023.11.006

Abstract

Abstract:

Objective To verify the effect of triamcinolone acetonide(TA) and normal saline(NS) irrigating salivary glands on long-term relief of xerostomia in patients with Sjögren’s syndrome(SS). Methods A total of 49 SS patients were randomly divided into control group (no irrigation, n=16), NS group(NS irrigation, n=17) and TA group(TA irrigation, n=16). The examinations of the unstimulated whole salivary flow(UWS), chewing-stimulated total salivary flow(SWS), citric acid-stimulated parotid flow(SPF), clinical xerostomia score(CODS), xerostomia scale(XI) and EULAR SS patient-reported index(ESSPRI) were conductedat 1 week before irrigation(0W) and 8 weeks(8W), 16 weeks(16W), 32 weeks(32W) and 40 weeks(40W) after irrigation. Results The follow-up of 14 cases in each group was completed. Compared with 0W, the SWS and SPF of 8W, 16W, 24W and 32W were increased after TA and NS irrigation(P<0.05), but there was no significant difference at 40W(P>0.05). Compared with 0W, ESSPRI(oral dryness domain) was decreased in TA and NS groups at 8W, 16W and 24W and 32W(P<0.05). The SWS and SPF of the TA group at 16W, 24W and 32W were higher than those of the control group(P<0.05). The CDOS in the NS group at 8W, 24W, and 32W were lower than those of the control group(P<0.05). Conclusion TA and NS irrigation of the major salivary glands can continuously relieve xerostomia in SS patients for 32 weeks.

Key words: irrigation, saliva, salivary glands, Sjögren’s syndrome, xerostomia

CLC Number:

R781.71

DU Hongming, ZHU Xiaodong, ZHAO Jing, XIAO Shanshan, FU Zhen. Salivary gland irrigation relieves xerostomia in patients with Sjögren’s syndrome:A single-blind randomized controlled clinical trial with 40-week follow-up[J]. Stomatology, 2023, 43(11): 996-1001.

Figures/Tables 6

Fig.1

Tab.1

Tab.2

Tab.3

Statistical results of saliva flow among the three groups at different time points"

比较项目	对照组		NS组				TA组
	与0W相比		与0W相比		与对照组相比		与0W相比		与对照组相比		与NS组相比
	差值(95%CI)	P	差值(95%CI)	P	差值(95%CI)	P	差值(95%CI)	P	差值(95%CI)	P	差值(95%CI)	P
UWS
0W					-0.001(-0.111,0.097)	0.888			0.010(-0.095,0.116)	0.844	-0.018(-0.120,0.084)	0.728
8W	-0.005(-0.023,0.014)	0.591	-0.047(-0.083,-0.011)	0.015^*	-0.049(-0.134,0.036)	0.248	-0.079(-0.134,-0.023)	0.009^*	-0.064(-0.150,0.023)	0.145	0.014(-0.069,0.098)	0.732
16W	0.004(-0.025,0.032)	0.773	-0.013(-0.045,0.018)	0.383	-0.024(-0.120,0.071)	0.609	-0.118(-0.147,-0.089)	<0.001^*	-0.111(-0.209,-0.014)	0.026^*	0.087(-0.007,0.181)	0.069
24W	0.009(-0.014,0.033)	0.406	<0.001(<0.001,<0.001)	1	-0.017(-0.111,0.078)	0.725	-0.031(-0.064,0.001)	0.059	-0.030(-0.126,0.066)	0.526	0.014(-0.079,0.106)	0.765
32W	0.003(-0.033,0.039)	0.856	-0.001(-0.022,0.019)	0.892	0.012(-0.064,0.088)	0.758	-0.031(-0.083,0.020)	0.207	0.024(-0.05,0.10)	0.532	0.012(-0.060,0.090)	0.738
40W	0.012(-0.011,0.036)	0.280	-0.001(-0.014,0.011)	0.820	0.021(-0.071,0.113)	0.649	0.006(-0.007,0.020)	0.316	-0.005(-0.098,0.089)	0.923	-0.025(-0.116,0.065)	0.573
SWS
0W					-0.027(-0.365,0.311)	0.873			-0.030(-0.374,0.313)	0.859	0.004(-0.328,0.335)	0.982
8W	-0.038(-0.089,0.012)	0.125	-0.102(0.194,0.010)	0.033^*	-0.090(-0.423,0.245)	0.589	-0.221(-0.334,-0.109)	0.001^*	-0.213(-0.555,0.128)	0.213	0.123(-0.206,0.452)	0.454
16W	-0.011(-0.191,0.170)	0.899	-0.136(-0.227,-0.045)	0.006^*	-0.152(-0.449,0.145)	0.307	-0.416(-0.566,-0.265)	<0.001^*	-0.435(-0.738,-0.133)	0.006^*	0.283(-0.008,0.575)	0.056
24W	0.014(-0.201,0.229)	0.891	-0.149(-0.215,-0.083)	<0.001^*	-0.189(-0.460,0.082)	0.166	-0.296(-0.440,-0.153)	0.001^*	-0.341(-0.616,-0.065)	0.017^*	0.151(-0.115,0.417)	0.256
32W	0.005(-0.206,0.216)	0.963	-0.144(-0.225,0.063)	0.002^*	0.175(-0.087,0.438)	0.185	-0.329(-0.490,0.167)	0.001^*	0.364(0.097,0.631)	0.009^*	0.188(-0.070,0.446)	0.148
40W	0.002(-0.010,0.013)	0.771	-0.001(-0.017,0.015)	0.930	0.029(-0.301,0.359)	0.860	0.011(-0.011,0.032)	0.305	0.021(-0.314,0.357)	0.899	-0.008(-0.331,0.316)	0.962
SPF
0W					0.014(-0.206,0.235)	0.897			-0.037(-0.262,0.187)	0.737	0.052(-0.165,0.268)	0.632
8W	-0.051(-0.103,0.001)	0.055	-0.087(-0.137,-0.036)	0.003^*	-0.022(-0.234,0.190)	0.837	-0.091(-0.171,-0.011)	0.029^*	-0.077(-0.293,0.138)	0.472	0.056(-0.152,0.264)	0.591
16W	-0.005(-0.132,0.122)	0.938	-0.090(-0.149,0.031)	0.005^*	-0.071(-0.261,0.119)	0.452	-0.268(-0.365,-0.171)	<0.001^*	-0.301(-0.494,-0.108)	0.003^*	0.229(0.043,0.416)	0.017^*
24W	0.021(-0.110,0.152)	0.736	-0.089(-0.165,-0.013)	0.025^*	-0.096(-0.264,0.072)	0.256	-0.209(-0.298,-0.121)	<0.001^*	-0.267(-0.439,-0.096)	0.003^*	0.172(0.006,0.337)	0.042^*
32W	0.017(-0.118,0.151)	0.789	-0.089(-0.173,-0.004)	0.041^*	0.091(-0.065,0.248)	0.244	-0.201(0.301,0.101)	0.001^*	0.256(0.097,0.415)	0.002^*	0.164(0.011,0.318)	0.036^*
40W	0.007(-0.015,0.029)	0.511	<0.001(-0.010,0.010)	1	-0.007(-0.217,0.202)	0.945	-0.003(-0.017,0.012)	0.679	0.047(-0.166,0.260)	0.656	0.054(-0.151,0.260)	0.595

Tab.3

Tab.4

Tab.5

Statistical results of index associated with SS among the three groups at different time points"

比较项目	对照组		NS组				TA组
	与0W相比		与0W相比		与对照组相比		与0W相比		与对照组相比		与NS组相比
	差值(95%CI)	P	差值(95%CI)	P	差值(95%CI)	P	差值(95%CI)	P	差值(95%CI)	P	差值(95%CI)	P
XI
0W					1.385(-3.763,6.532)	0.589			0.242(-4.990,5.474)	0.926	1.143(-3.905,6.191)	0.650
8W	0.462(-0.342,1.265)	0.235	2.200(0.484,3.916)	0.016^*	3.123(-2.131,8.377)	0.236	4.500(1.719,7.281)	0.004^*	4.280(-1.060,9.621)	0.113	-1.157(-6.310,3.995)	0.652
16W	0.692(-0.243,1.628)	0.133	2.200(0.190,4.210)	0.034^*	2.892(-1.726,7.511)	0.213	6.214(3.591,8.838)	<0.001^*	5.764(1.070,10.458)	0.017^*	-2.871(-7.401,1.658)	0.207
24W	0.692(-0.210,1.595)	0.121	2.133(0.298,3.968)	0.026^*	2.826(-1.920,7.572)	0.236	4.857(2.420,7.295)	0.001^*	4.407(-0.418,9.231)	0.072	-1.581(-6.235,3.073)	0.496
32W	1.462(0.315,2.609)	0.017	2.733(1.322,4.145)	0.001^*	-2.656(-7.005,1.693)	0.224	5.286(2.564,8.007)	0.001^*	-4.066(-8.486,0.355)	0.070	-1.410(-5.674,2.855)	0.508
40W	0.308(-0.265,0.880)	0.264	0.133(-0.328,0.595)	0.546	-1.210(-6.464,4.044)	0.644	0.143(-0.568,0.854)	0.671	-0.077(-5.417,5.264)	0.977	1.133(-4.019,6.286)	0.659
CODS
0W					0.221(-0.526,0.967)	0.554			0.368(-0.391,1.127)	0.332	-0.148(-0.880)	0.686
8W	0.077(-0.382,0.536)	0.721	0.333(-0.008,0.675)	0.055	0.477(-0.035,0.989)	0.067	0.500(0.124,0.876)	0.013^*	0.791(0.271,1.311)	0.004^*	-0.314(-0.816,0.188)	0.213
16W	0.385(-0.008,0.778)	0.054	0.733(0.244,1.223)	0.006^*	0.569(-0.369,1.507)	0.227	0.643(0.213,1.073)	0.007^*	0.626(-0.327,1.580)	0.192	-0.057(-0.977,0.863)	0.901
24W	0.231(-0.272,0.734)	0.337	0.267(-0.062,0.595)	0.104	0.256(-0.301,0.814)	0.358	0.571(0.198,0.945)	0.006^*	0.709(0.142,1.275)	0.016^*	-0.452(-0.999,0.094)	0.102
32W	0.231(-0.207,0.669)	0.273	0.067(-0.187,0.320)	0.582	-0.056(-0.670,0.557)	0.853	0.571(0.198,0.945)	0.006^*	-0.709(-1.333,-0.085)	0.027^*	-0.652(-1.254,-0.050)	0.034^*
40W	-0.077(-0.245,0.091)	0.337	-0.067(-0.210,0.076)	0.334	-0.231(-0.980,0.518)	0.537	-0.143(-0.353,0.067)	0.165	-0.302(-1.063,0.459)	0.427	-0.071(-0.806,0.663)	0.845
ESSPRI (总分)
0W					0.221(-3.046,3.487)	0.892			-0.703(-4.024,2.627)	0.671	0.924(-2.280,4.127)	0.563
8W	-0.231(-1.540,1.078)	0.708	1.667(-0.236,3.570)	0.081	2.118(-1.719,5.955)	0.271	3.214(1.547,4.881)	0.001^*	2.742(-1.158,6.642)	0.163	-0.624(-4.386,3.139)	0.739
16W	0.769(-0.813,2.352)	0.310	3.000(0.577,5.423)	0.019^*	2.451(-1.405,6.308)	0.206	8.214(6.251,10.178)	<0.001^*	6.742(2.822,10.661)	0.001^*	-4.290(-8.072,-0.509)	0.027^*
24W	0.846(-0.104,1.797)	0.076	1.800(-0.533,4.133)	0.120	1.174(-2.683,5.032)	0.542	4.500(2.609,6.391)	<0.001^*	2.951(-0.970,6.871)	0.136	-1.776(-5.558,2.007)	0.348
32W	0.692(-0.575,1.960)	0.257	2.067(0.201,3.933)	0.032	-1.595(-5.082,1.892)	0.361	4.643(2.713,6.573)	<0.001^*	-3.247(-6.792,0.297)	0.071	-1.652(-5.072,1.768)	0.334
40W	-0.615(-1.377,0.147)	0.104	<0.001(-0.694,0.694)	1	-0.836(-4.176,2.504)	0.616	0.286(-0.446,1.017)	0.414	-0.198(-3.593,3.197)	0.907	0.638(-2.638,3.914)	0.696
ESSPRI (口干症状)
0W					-0.800(-2.052,0.452)	0.204			-0.857(-2.130,0.416)	0.181	0.057(-1.171,1.285)	0.926
8W	-0.077(-0.598,0.444)	0.753	0.600(0.192,1.008)	0.007^*	-0.123(-1.214,0.968)	0.821	0.714(0.140,1.288)	0.019^*	-0.066(-1.175,1.043)	0.905	-0.057(-1.127,1.013)	0.915
16W	-0.077(-0.653,0.500)	0.776	0.533(0.179,0.888)	0.006^*	-0.190(-1.162,0.782)	0.695	1.571(0.903,2.240)	<0.001^*	0.791(-0.197,1.779)	0.113	-0.981(-1.934,-0.028)	0.044^*
24W	0.077(-0.500,0.653)	0.776	0.600(0.250,0.950)	0.003^*	-0.277(-1.218,0.664)	0.555	1.357(0.821,1.893)	<0.001^*	0.423(-0.534,1.380)	0.377	-0.700(-1.623,0.223)	0.133
32W	-0.385(-1.223,0.453)	0.337	0.467(-0.040,0.974)	0.068^*	-0.051(-1.030,0.928)	0.916	1.500(0.830,2.170)	<0.001^*	-1.027(-2.023,-0.032)	0.043	-0.976(-1.936,-0.016)	0.046^*
40W	-0.154(-0.489,0.181)	0.337	0.267(0.013,0.520)	0.041^*	0.379(-0.796,1.555)	0.518	0.071(-0.203,0.345)	0.583	0.632(-0.563,1.827)	0.291	0.252(-0.901,1.406)	0.660

Tab.5

References 24

[1]	Thorlacius GE, Björk A, Wahren-Herlenius M. Genetics and epigenetics of primary Sjögren syndrome: Implications for future therapies[J]. Nat Rev Rheumatol, 2023, 19(5):288-306. doi: 10.1038/s41584-023-00932-6 pmid: 36914790
[2]	Vehof J, Utheim TP, Bootsma H, et al. Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren’s syndrome[J]. Clin Exp Rheumatol, 2020, 38 Suppl 126(4):301-309.
[3]	Choudhry HS, Hosseini S, Choudhry HS, et al. Updates in diagnostics, treatments, and correlations between oral and ocular manifestations of Sjogren’s syndrome[J]. Ocul Surf, 2022, 26:75-87. doi: 10.1016/j.jtos.2022.08.001 pmid: 35961534
[4]	Wu KY, Kulbay M, Tanasescu C, et al. An overview of the dry eye disease in Sjögren’s syndrome using our current molecular understanding[J]. Int J Mol Sci, 2023, 24(2):1580. doi: 10.3390/ijms24021580
[5]	Vujovic S, Desnica J, Stevanovic M, et al. Oral health and oral health-related quality of life in patients with primary Sjögren’s syndrome[J]. Medicina, 2023, 59(3):473. doi: 10.3390/medicina59030473
[6]	Farag AM, Holliday C, Cimmino J, et al. Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivation[J]. Oral Dis, 2019, 25(8):1937-1944. doi: 10.1111/odi.13192 pmid: 31520497
[7]	Al Hamad A, Lodi G, Porter S, et al. Interventions for dry mouth and hyposalivation in Sjögren’s syndrome: A systematic review and meta-analysis[J]. Oral Dis, 2019, 25(4):1027-1047. doi: 10.1111/odi.12952 pmid: 30086205
[8]	Garlapati K, Kammari A, Badam RK, et al. Meta-analysis on pharmacological therapies in the management of xerostomia in patients with Sjogren’s syndrome[J]. Immunopharmacol Immunotoxicol, 2019, 41(2):312-318. doi: 10.1080/08923973.2019.1593448
[9]	Lee CN, Kim JE, Huh KH, et al. Therapeutic effect of intraductal irrigation of the salivary gland: A technical report[J]. Imaging Sci Dent, 2017, 47(2):123-127. doi: 10.5624/isd.2017.47.2.123 pmid: 28680849
[10]	Grande-Moreillo C, Margarit-Mallol J, Fuentes-Carretero S, et al. Parotid irrigation: A promising option for juvenile recurrent parotitis[J]. Am J Otolaryngol, 2022, 43(3):103398. doi: 10.1016/j.amjoto.2022.103398
[11]	Kim JE, Lee SS, Lee CN, et al. Therapeutic effect of intraductal saline irrigation in chronic obstructive sialadenitis[J]. BMC Oral Health, 2020, 20(1):86. doi: 10.1186/s12903-020-01078-7
[12]	Karagozoglu KH, Vissink A, Forouzanfar T, et al. Sialendoscopy enhances salivary gland function in Sjögren’s syndrome: A 6-month follow-up, randomised and controlled, single blind study[J]. Ann Rheum Dis, 2018, 77(7):1025-1031. doi: 10.1136/annrheumdis-2017-212672 pmid: 29475854
[13]	Karagozoglu KH, Vissink A, Forouzanfar T, et al. Sialendoscopy increases saliva secretion and reduces xerostomia up to 60 weeks in Sjögren’s syndrome patients:A randomized controlled study[J]. Rheumatology, 2021, 60(3):1353-1363. doi: 10.1093/rheumatology/keaa284 pmid: 32949144
[14]	Du HM, Fu Z, Zhong Y, et al. A randomized controlled trial to verify the irrigation of salivary glands in relieving xerostomia in patients with Sjögren’s syndrome[J]. Front Immunol, 2022, 13:1039599. doi: 10.3389/fimmu.2022.1039599
[15]	Jager DJ, Karagozoglu KH, Maarse F, et al. Sialendoscopy of salivary glands affected by sjögren syndrome:A randomized controlled pilot study[J]. J Oral Maxillofac Surg, 2016, 74(6):1167-1174. doi: 10.1016/j.joms.2015.12.019
[16]	Cornec D, Saraux A, Cochener B, et al. Level of agreement between 2002 American-European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren’s syndrome and reasons for discrepancies[J]. Arthritis Res Ther, 2014, 16(2):R74.
[17]	Osailan SM, Pramanik R, Shirlaw P, et al. Clinical assessment of oral dryness:Development of a scoring system related to salivary flow and mucosal wetness[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2012, 114(5):597-603. doi: 10.1016/j.oooo.2012.05.009
[18]	Jager DHJ, Bots CP, Forouzanfar T, et al. Clinical oral dryness score:Evaluation of a new screening method for oral dryness[J]. Odontology, 2018, 106(4):439-444. doi: 10.1007/s10266-018-0339-4 pmid: 29356914
[19]	Hijjaw O, Alawneh M, Ojjoh K, et al. Correlation between Xerostomia index, Clinical Oral Dryness Scale, and ESSPRI with different hyposalivation tests[J]. Open Access Rheumatol, 2019, 11:11-18.
[20]	Santiago PHR, Song Y, Hanna K, et al. Degrees of xerostomia? A rasch analysis of the xerostomia inventory[J]. Community Dent Oral Epidemiol, 2020, 48(1):63-71. doi: 10.1111/cdoe.v48.1
[21]	Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)[J]. Ann Rheum Dis, 2016, 75(2):382-389.
[22]	Navazesh M. Methods for collecting saliva[J]. Ann N Y Acad Sci, 1993, 694:72-77. doi: 10.1111/nyas.1993.694.issue-1
[23]	Woo JS, Lu DY. Procurement, transportation, and storage of saliva, buccal swab, and oral wash specimens[J]. Methods Mol Biol, 2019, 1897:99-105. doi: 10.1007/978-1-4939-8935-5_10 pmid: 30539438
[24]	Izumi M, Eguchi K, Nakamura H, et al. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjögren’s syndrome[J]. Ann Rheum Dis, 1998, 57(8):464-469. pmid: 9797551

项目	基线情况
年龄/岁	46.07±7.13
女性/男性	13∶1
病程/年	3.48±1.47
对照组	3.33±0.89
NS组	3.93±1.83
TA组	3.14±1.46
原发SS	28(66.67%)
对照组	9(64.29%)
NS组	10(71.43%)
TA组	9(64.29%)
继发SS	14(33.33%)
对照组	5(35.71%)
NS组	4(28.57%)
TA组	5(35.71%)
血浆抗体阳性
anti-SSA	36(81.82%)
anti-SSB	34(80.95%)
RF	24(57.14%)
ANA	20(47.62%)
唇腺活检阳性	37(88.10%)
施墨试验阳性	36(85.71%)
基线UWS/(mL/min)
对照组	0.14±0.13
NS组	0.14±0.15
TA组	0.13±0.13
基线SWS/(mL/min)
对照组	0.34±0.43
NS组	0.37±0.40
TA组	0.37±0.38
基线SPF/(mL/min)
对照组	0.21±0.28
NS组	0.19±0.23
TA组	0.24±0.34
XI	42.81±6.59
ESSPRI(总分)	21.30±4.18
ESSPRI(口干症状)	6.57±1.64
CODS	4.95±0.96

各时间点	UWS			SWS			SPF
各时间点	对照组	NS组	TA组	对照组	NS组	TA组	对照组	NS组	TA组
0W	0.14±0.13	0.14±0.15	0.13±0.13	0.34±0.43	0.37±0.40	0.37±0.38	0.21±0.28	0.19±0.23	0.24±0.34
8W	0.14±0.11	0.19±0.11	0.20±0.10	0.38±0.44	0.47±0.40	0.60±0.47	0.26±0.32	0.28±0.24	0.33±0.26
16W	0.13±0.10	0.16±0.14	0.24±0.13	0.35±0.17	0.51±0.40	0.79±0.50	0.21±0.12	0.28±0.24	0.51±0.33
24W	0.13±0.11	0.14±0.15	0.16±0.10	0.33±0.12	0.52±0.40	0.67±0.44	0.19±0.09	0.28±0.19	0.45±0.31
32W	0.13±0.08	0.14±0.13	0.16±0.07	0.34±0.11	0.51±0.40	0.70±0.41	0.19±0.08	0.28±0.19	0.45±0.28
40W	0.12±0.11	0.14±0.14	0.12±0.11	0.34±0.44	0.37±0.39	0.36±0.46	0.20±0.27	0.19±0.22	0.25±0.32

各时间点	XI			CODS			ESSPRI(总分)			ESSPRI(口干症状)
各时间点	对照组	NS组	TA组	对照组	NS组	TA组	对照组	NS组	TA组	对照组	NS组	TA组
0W	43.38±5.9	42.00±7.12	43.14±7.00	5.15±0.90	4.93±1.03	4.79±0.97	21.15±4.54	20.93±4.83	21.86±3.21	6.00±1.68	6.80±1.61	6.86±1.61
8W	42.92±5.95	39.80±7.36	38.64±7.07	5.08±0.64	4.60±0.74	4.29±0.61	42.92±5.95	19.27±5.40	18.64±4.58	6.08±1.26	6.20±1.52	6.14±1.46
16W	42.69±5.64	39.80±5.83	36.93±6.55	4.77±1.09	4.20±1.52	4.14±0.95	20.38±3.20	17.93±6.18	13.64±5.03	6.08±1.12	6.27±1.44	5.29±1.20
24W	42.69±6.06	39.87±6.37	38.29±6.12	4.92±0.49	4.66±0.72	4.21±0.89	20.31±4.37	19.13±5.88	17.36±4.60	4.92±0.49	6.20±1.47	5.50±1.09
32W	41.92±4.73	39.27±6.15	37.86±5.93	4.92±0.64	4.87±0.92	4.21±0.80	20.46±4.54	18.87±4.60	17.21±4.51	6.38±1.50	6.33±1.35	5.36±0.93
40W	43.08±6.14	41.87±7.12	43.00±7.18	5.23±0.93	5.00±1.00	4.93±1.00	21.77±4.21	20.93±5.06	21.57±3.61	6.15±1.46	6.53±1.46	6.79±1.67

Salivary gland irrigation relieves xerostomia in patients with Sjögren’s syndrome:A single-blind randomized controlled clinical trial with 40-week follow-up

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 24

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Lan, LI Yanping, HE Lina, PAN Shuang, WANG Ranxu, NIU Yumei. Effects of Morinda citrifolia combined with EDTA root canal irrigation on the mechanical properties of dentin [J]. Stomatology, 2023, 43(8): 690-696.
[2]	QU Chaojie,GUO Wei. The effect of smear layer removal after cleaning root canals in different length and curvature with Er: YAG laser irrigation [J]. Stomatology, 2023, 43(5): 427-433.
[3]	LYU Ying,XU Rui,ZHANG Qinqin,SHI Banruo,WU Qiaochu,WEI Xin. Effects of irrigants on mixed biofilm of Enterococcus faecalis and Candida albicans in standard root canal models [J]. Stomatology, 2023, 43(5): 434-438.
[4]	ZHANG Pengxin, FEI Runxin, XU Hui. Research progress of tight junction protein Claudin of salivary glands [J]. Stomatology, 2023, 43(2): 176-181.
[5]	XIAO Min, LIU Jin, FAN Xiaomin, WU Haoze, WANG Jueyu, WANG Kejing, LI Na, JIANG Wenkai, MEI Xiaohan. The effect of sonic activated device used for different time on intracanal smear layer removal: An SEM analysis [J]. Stomatology, 2023, 43(1): 46-51.
[6]	CHEN Yiling, FENG Shuqi, CAO Liren, WU Dan, PENG Yiran. Progress of research on the effects of chronic asthma on oral health [J]. Stomatology, 2022, 42(8): 754-758.
[7]	XU Yingjiao, WANG Shan. Research progress on the role of salivary exosomes in oral squamous cell carcinoma [J]. Stomatology, 2022, 42(7): 664-667.
[8]	SHA Sha, LU Lingbo, GUO Peipei, CHEN Shu, JIN Muhan, XU Rongyao. Clinical study on correlation between miRNA-143/145 in saliva and estrogen-deficient osteoporosis [J]. Stomatology, 2022, 42(6): 515-520.
[9]	. Longitudinal study on the relationship between infant oral microbial diversity and mother's caries susceptibility [J]. , 2020, 40(3): 239-243.
[10]	. Expression of matrix metalloproteinase-3 in salivary and labial gland tissue in patients with Sj?rgen syndrome [J]. , 2019, 39(8): 701-705.
[11]	. Five cases of maxillary sinusitis after maxillary sinus lifting were treated by maxillary sinus anterior lateral wall puncture and irrigation [J]. , 2019, 39(11): 1032-1037.
[12]	. Analysis of inhibitory effects of three endodontic irrigations on the pathogens in root canals [J]. , 2019, 39(1): 25-29.
[13]	. The clinical research of the rotary nickeltitanium instruments and the ultrasonic root canal irrigation which were applied to the single-visit root canal therapy of the chronic apical periodontitis [J]. , 2018, 38(2): 162-165.
[14]	. Effect of culture in vitro on human salivary microflora by high throughput sequencing [J]. , 2018, 38(12): 1062-1067.
[15]	. Salivary glands mucosa-associated lymphoid tissue lymphoma in head and neck: A case report and systematic literature review [J]. , 2018, 38(12): 1137-1140.